Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (308)	3/15/2004 1:26:37 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Vion Licenses Melasyn Rights DOW JONES NEWSWIRES Vion Pharmaceuticals Inc. (VION) is licensing its Melasyn technology to Johnson & Johnson (JNJ). NEW HAVEN, Conn. -- Vion Pharmaceuticals Inc. (VION) signed a worldwide nonexclusive agreement to license its Melasyn technology to Johnson & Johnson (JNJ) Consumer Cos. Melasyn is a synthetic form of melanin that dissolves readily in water. Melanin is a pigment formed by cells in the skin that gives skin its color and protects it from sun damage by absorbing ultraviolet rays. In a press release Monday, Vion said it won't receive any upfront or milestone payments. If products including Vion's technology are developed, Vion will receive a royalty based on sales in countries where it has issued patents. President Howard B. Johnson said he couldn't disclose further details about the agreement. In 1998, the company licensed its Melasyn technology to San-Mar Laboratories. Shares of Vion were trading recently at $3.53, up 10 cents, or 2.9%, in Nasdaq trading.